Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLUMINS: Dulaglutide for Reduction of Myocardial Injury After Non-Cardiac Surgery
NCT06324461Phase 4Recruiting
- Sponsor
- The University of Hong Kong
- Start
- Mar 2024
- Primary completion
- Dec 2028
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of dulaglutide biosimilar 14028 injection in Myocardial injury, sponsored by The University of Hong Kong. Started Mar 2024; status: recruiting.
02
Drugs
dulaglutide biosimilar 14028 injection
03
Conditions
Myocardial injury
Beyond the preview
Go deeper on NCT06324461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06324461.